PersonGen BioTherapeutics is advancing a CAR-T cell therapy targeting CD19/CD20 for patients with advanced hematological malignancies. The market for CAR-T therapies is rapidly expanding, particularly in the treatment of B-cell malignancies such as non-Hodgkin lymphoma and acute lymphoblastic leukemia. Given the high unmet need in this patient population, successful outcomes could position PersonGen favorably against established players like Novartis and Gilead. The trial's focus on patients with limited treatment options enhances its potential market appeal. However, the competitive landscape is intense, necessitating robust efficacy and safety data to ensure differentiation.